In a strategic move designed to bolster its bioeconomy, China’s State Council recently approved a new pilot program in the Jiangsu Free Trade Zone (FTZ), which will be used as a testing ground for system-wide innovation in the biopharma sector. One of the core innovations of the plan is

Yesterday, the Trump administration posted notices indicating that it would be proceeding with national security investigations under Section 232 of the Trade Expansion Act of 1962 related to imports of semiconductors and semiconductor manufacturing equipment and of pharmaceuticals and pharmaceutical ingredients.

Last week, a group of European Union member states issued a paper raising concerns about medicine shortages, and in that context criticizing dependence on China for inputs used in those products.